Abstract: The disclosure relates to a method for manufacturing a biocompatible wire, a biocompatible wire comprising a biocompatible metallic material and a medical device comprising such wire. The method for manufacturing a biocompatible wire comprises providing a workpiece of a biocompatible metallic material, cold working the workpiece into a wire, and annealing the wire, wherein a cold work percentage is 97 to 99%, wherein the cold working is a drawing with a die reduction per pass ratio in a range of 6 to 40%, and wherein the annealing is done in a range of 850 to 1100° C.

Abstract: The disclosure relates to a method for manufacturing a biocompatible wire, a biocompatible wire comprising a biocompatible metallic material and a medical device comprising such wire. The method for manufacturing a biocompatible wire comprises providing a workpiece of a biocompatible metallic material, cold working the workpiece into a wire, and annealing the wire, wherein a cold work percentage is 97 to 99%, wherein the cold working is a drawing with a die reduction per pass ratio in a range of 6 to 40%, and wherein the annealing is done in a range of 850 to 1100° C.

Abstract: The disclosure relates to a method for manufacturing a biocompatible wire, a biocompatible wire comprising a biocompatible metallic material and a medical device comprising such wire. The method for manufacturing a biocompatible wire comprises providing a workpiece of a biocompatible metallic material, cold working the workpiece into a wire, and annealing the wire, wherein a cold work percentage is 97 to 99%, wherein the cold working is a drawing with a die reduction per pass ratio in a range of 6 to 40%, and wherein the annealing is done in a range of 850 to 1100° C.

Abstract: One aspect relates to a method for manufacturing a composite wire, including providing a first part in form of a rod, providing a second part in form of a tube surrounding the rod at least partially to form a rod-tube assembly, providing a clad part in form of a cylinder surrounding the rod-tube assembly at least partially to form a cladded rod-tube assembly, and extruding the cladded rod-tube assembly to form the composite wire. The second part includes an alloy comprising the following alloy components: a) Cr in the range from about 10 to about 30 wt. %; b) Ni in the range from about 20 to about 50 wt. %; c) Mo in the range from about 2 to about 20 wt. %; d) Co in the range from about 10 to about 50 wt. %; wherein the Al content of the alloy is less than about 0.01 wt. %; wherein each wt. % is based on the total weight of the alloy.

Abstract: One aspect relates to a coil comprising at least two composite wires. The composite wire includes a first part and a second part. The first part is a metallic component. The second part includes an alloy of: a) Cr in the range from about 10 to about 30 wt. %; b) Ni in the range from about 20 to about 50 wt. %; c) Mo in the range from about 2 to about 20 wt. %; d) Co in the range from about 10 to about 50 wt. %. The Al content of the Cr, Ni, Mo and Co alloy is less than about 0.01 wt. % and each wt. % is based on the total weight of the alloy. The first part may at least partially surround the second part when seen in a cross section.

Abstract: One aspect relates to a method for manufacturing a cable. The method for manufacturing the cable includes the steps of providing several raw wires made of a wire material, drawing the raw wires into wires, coiling the wires into a cable, and heat treating the cable. The wire material includes an alloy including the following alloy components: a) Cr in the range from about 10 to about 30 wt. %; b) Ni in the range from about 20 to about 50 wt. %; c) Mo in the range from about 2 to about 20 wt. %; d) Co in the range from about 10 to about 50 wt. %. The Al content of the Cr, Ni, Mo and Co alloy is less than about 0.01 wt. % and each wt. % is based on the total weight of the alloy.

Abstract: One aspect relates to a method for manufacturing a passivated product, a passivated product, and a medical device comprising such passivated product. The passivated product comprises a raw product and a passivation coating. The raw product is made at least partially of an alloy comprising Cr, Ni, Mo and Co, in one embodiment, with tightly controlled levels of impurities. The method for manufacturing the passivated product comprises a providing of a raw product and a passivating of a surface of the raw product at least partially to provide a passivated product with a passivation coating. The raw product is made at least partially of an alloy comprising the following alloy components: a) Cr in the range from about 10 to about 30 wt. %; b) Ni in the range from about 20 to about 50 wt. %; c) Mo in the range from about 2 to about 20 wt. %; d) Co in the range from about 10 to about 50 wt. %. The Al content of the Cr, Ni, Mo and Co alloy is less than about 0.01 wt. % and each wt.

Abstract: A process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime is described which includes: (i) reacting benzofuran-3(2H)-one O-methyl oxime (1) with at least one nitrite selected from n-butyl nitrite and tert-butyl nitrite, in the presence of a metal alkoxide to form (2Z,32)-2,3-benzofuran-dione O3-methyl dioxime (2) as the predominant isomer; (ii) reacting the (2Z,3Z)-2,3-benzofuran-dione O-methyl dioxime (2) with 2-haloethanol to form (2Z,3Z)-benzofuran-2,3-dione 02-(2-hydroxyethyl) O3-methyl dioxime (3); and (iii) reacting the (2Z,3Z)-benzofuran-2,3-dione 02-(2-hydroxyethyl) & -methyl dioxime (3) with an acid to form (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone (9-methyl oxime (4);

Abstract: A process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime is described which includes: (i) reacting benzofuran-3(2H)-one O-methyl oxime (1) with at least one nitrite selected from n-butyl nitrite and tert-butyl nitrite, in the presence of a metal alkoxide to form (2Z,32)-2,3-benzofuran-dione O3-methyl dioxime (2) as the predominant isomer; (ii) reacting the (2Z,3Z)-2,3-benzofuran-dione O-methyl dioxime (2) with 2-haloethanol to form (2Z,3Z)-benzofuran-2,3-dione 02-(2-hydroxyethyl) O3-methyl dioxime (3); and (iii) reacting the (2Z,3Z)-benzofuran-2,3-dione 02-(2-hydroxyethyl) & -methyl dioxime (3) with an acid to form (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone (9-methyl oxime (4);